2025 POSTER PRESENTATIONS

Preliminary List as of March 21

AbbVie, Inc.
Novel Small Molecule Inhibitors of E3 Ligase ITCH Identified by DNA-Encoded Chemical Libraries

AustinPx
Formulation Strategies for Enabling “Undevelopable” Compounds

Axcelead
Identification of Covalent JNK Inhibitor

BioAscent Discovery Ltd.
Discovery and Characterisation of a Novel TRPML1 Agonist

BioDuro
High-Throughput Peptide Library: Rapid Synthesis of Linear and Cyclic Peptides Without Purification Needed

Biortus
Exploring the Power of Structural Biology on Degrader Discovery

BiosensingUSA
Exploring the Influence of Cell Surface Post-Translational Modification (Glycosylation) on the Potency of Therapeutic Targeting in Pancreatic Cancer

Carterra
Increasing DNA Encoded Library Screening Resolution Using HT-SPR

Carterra
Massively Parallel SPR-Based Fragment Screening of Kinase Arrays

Carterra
Selectivity and Cooperativity of PROTAC®s Using HT-SPR

Cayman Chemical Company
Biophysical Characterization of MR1 (K43A)/β2M Complex

Cayman Chemical Company
Fragment-Based Drug Discovery (FBDD) Approach for IRAK4

CellarisBio
Combined Application of CRISPR and MICRO-TAG Cell Target Engagement for Discovery of a Novel CHD4 Inhibitor in Therapy-Resistant Gliomas

CellarisBio
Live-Cell Real-Time Step-Gradient Quantification of Drug-Target Engagement for Rapid Drug Discovery

CellarisBio
MICRO-TAG Cell Target Engagement Platform - From Discovery to Optimization

CellarisBio
MICRO-TAG: A Novel Fluorescence-Based Real-Time Cellular Target Engagement Platform for Drug Discovery

Chempartner
Approach to Rational Identification of Lead Molecular Glue Degraders for Casein Kinase 1α

Chungnam National University
A Novel Kinase Inhibitor Design Platform Based on Topological Water Networks

Chungnam National University
Exploring the Impact of Water on the Stability of the Collagen Triple Helix

City of Hope Medical Center
Structure-Based Drug Design of Selective Inhibitors to Target PCNA Function in Solid and Liquid Cancers

Concept Life Sciences
Concept’s ‘D2B’ Approach to PROTAC Drug Discovery - A Streamlined Workflow for Innovative Fast Tracking of PROTACs

Concept Life Sciences
Introducing BioPALS – A Versatile Hit Identification Technology Powered by AI and Enabled by GCI

Cresset
Applying Molecular Simulations to Qualitatively Rank Degrader Designs

Curia
Accelerating Discovery Success with Structure-Guided Drug Design: A Worked Example from a Challenging DNA-Repair Target, Artemis

Cytiva
Remove Your Analysis Bottleneck—Biacore Intelligent Analysis Software™

DEL Source
Fast-Tracking Covalent Drug Discovery with AI-Powered CovScan Platform

DEL Source
High-Quality and Cost-Effective DNA-Encoded Library (DEL) and Drug Discovery Services from Del-Source and Presude Lifesciences

Development Center for Biotechnology
Development of Novel Selective FPR1 Antagonist Against Neutrophil-Mediated Inflammatory Disease

Domainex Ltd.
Characterisation of Reversible and Irreversible Covalent Inhibitors Using a Novel LC-MS Based Covalent Fragment Screening Workflow

Domainex Ltd.
Integral Membrane Proteins for Biophysics and Cryo-EM Applications – Case Study of the Ion Channel TrpML3

Domainex Ltd.
Leveraging Bivalent Molecules and Biophysical / Biochemical Techniques for Enhanced Therapeutic Potential

Domainex Ltd.
Using Direct-to-Biology in a Spectral Shift-PoLiPa Platform to Enable Fast Fragment Follow-Up for Adenosine A2a Antagonists

Edelris SAS
Structure-Based Discovery of First Inhibitors Targeting the Helicase Activity of Human PIF1

eMolecules, Inc.
Rapid, Automated Synthesis of Custom Fluorinated Libraries for an NMR-Based Hit Discovery Platform

eMolecules, Inc.
Synple 4.0 Discovery Platform: Automated Synthesis of Protein Degraders for Drug Discovery

Eurofins Cerep
Emerging Hit Finding Technology: High Throughput Spectral Shift (HT-SpS) for Binder and Molecular Glue Identification

Eurofins DiscoverX
Advancing Obesity Therapeutics with Functional & Binding Cell-Based Assays for GLP-1, GIP, & Glucagon

Eurofins Discovery
Comprehensive Characterization of BTK Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Non-Covalent Mechanistic Signatures

Eurofins Discovery
Integrated Solutions for STAT Inhibition and Targeted Protein Degradation: Enabling Novel Therapies for Cancer, Inflammation and Autoimmune Disease

Eurofins Discovery
The Eurofins Emerald Database: A Foundation for AI ADMET and Off-Target Liability Prediction

Evolvus
The Discovery of Novel E3 Ligase Ligands with Proximers

FIMECS, Inc.
Phenotypic-First Approach for Discovery of Targeted Protein Degraders by RaPPIDS™ Platform to Expand the Landscape of E3 Ligases

Genentech, Inc.
Structural Insights into TEAD Inhibition: Targeting the Lipid-Binding Pocket for Cancer Therapy

Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology
Fragment-Based Screening via Bead Display: Exploiting Avidity Effects for the Identification of Low-Affinity Binders

HITS Co., Ltd.
Identifying MARK4 Inhibitors Using RxnFlow - A Target-Oriented Synthesizable Molecule Generation Model

ICE Bioscience
VAV1-Induced Proximity: Insights from Molecule Glue Profiling

IKTOS
Integration of AI-Optimized Design and Synthesis Toward the Identification of PKMYT1 Inhibitors

Institute of Biochemistry and Biophysics of the Polish Academy of Sciences
Application of Vision Transformers to Protein-Ligand Affinity Prediction

Inte:Ligand GmbH
Addressing Challenging Targets in Early Drug Discovery: Recent Applications of LigandScout

Inte:Ligand GmbH
The NeuroDeRisk Toolbox: De-Risking Neurotoxicity in Drug Discovery

IRBM Science Pk SpA
Enabling Rapid Hit Identification: Integrated Platforms for PROTACs and Covalent Fragments

Laboratorio Nacional de Computacao Cientifica (LNCC)
A Generative Evolutionary Many-Objective Framework for de novo Drug Design

Lawrence Berkeley National Laboratory
Fragment Based Ligand Generation Guided by Geometric Deep Learning

Life Chemicals, Inc.
Advanced PPI-Targeting Screening Libraries

Life Chemicals, Inc.
Fragment Libraries for FBDD

Malvern Panalytical
Interaction Analysis with Nucleic Acids as Targets Using GCI and ITC

Mestrelab Research
Handling the Big Volume NMR and LC-MS Data for Fragment-Based Hit Screening and Making the Results Ready for AI Machine Learning

Mestrelab Research
Streamlining the High Throughput Reaction (HTE) Optimization Journey Through Automation of Data Workflows

Molport
Targeted and Technology-Driven Profiling of the Molport Fragment Chemical Space

National Institutes of Health, National Center for Advancing Translational Sciences
An NMR-Based Fragment Screening Approach to Identify LCAT Modulators

National Institutes of Health, National Center for Advancing Translational Sciences
Use of Virtual Screening and In Vitro Assays to Identify Small Molecules for Their Potential Treatment of Opioid Tolerance

NovAliX SAS
Identification of a submicromolar BRD4 PROTAC Degrader from a Moderately Potent DEL Hit: Harnessing the synergy of DEL & PROTAC technologies

Optibrium Ltd.
Application of Deep Learning Imputation to Peptide Bioactivity and Property Prediction

Optibrium Ltd.
Macrocyclic Peptide Optimisation: Integrating Computational Approaches with Biophysical Data

Optibrium Ltd.
Rapid AI Generation of Optimised Compound Designs, Guided by User Interaction

Pelago Bioscience AB
Enhancing Primary Screening with CETSA®

Pohang Accelerator Laboratory
Crystallographic Fragment Screening Facility in Korea for Structure-Based Drug Discovery

Portal Biotechnologies
Enabling Novel Live Cell Assays with a Silicon Membrane-Based Platform for Mechanical Delivery of Impermeable Small Molecules, Peptides, and Probes to Accelerate Early Drug Discovery

Promega Corporation
A Bioluminescent and Homogeneous Assay for Monitoring GPCR-Mediated cAMP Modulation and Adenylate Cyclase Activity

Promega Corporation
Automation-Enabled Target Engagement Selectivity Screening of Small Molecule Kinase Inhibitors

Promega Corporation
De-Risking CRBN-Recruiting Degraders: Characterizing Neosubstrate Degradation Specificity and Selectivity

Promega Corporation
Live Cell NanoBRET® TE Assays for WRN and Synthetic Lethal Targets in the DNA Damage Response Pathway

Promega Corporation
Next-Generation Tools for Kinetic TPD Assays: Improving Live-Cell Analysis

Promega Corporation
The NanoBRET® TE Intracellular EGFR Assay: A Quantitative Assay to Determine Target Engagement to Dimeric, Membrane-Localized EGFR in Live Cells

Q-MOL LLC
Allosteric targeting of viral processing proteinases of West Nile, Zika, Dengue and Hepatitis C viruses using Q-MOL in silico drug discovery platform

Reaction Biology Corporation
Development of Biochemical Assay Tools to Enhance Drug Discovery Efforts Targeting RNA Modification Regulators

SandboxAQ
Comprehensively Benchmarking AQFEP: Assessing the Accuracy and Generalizability Across Diverse Chemical Space

SandboxAQ
Integrated AI and Physics-Based Methodologies for In Silico Target Identification

SandboxAQ
Next Generation Physics-Based Scoring Function Unlocks Superior ML Driven Chemical Space Exploration

Sanford Burnham Prebys Medical Discovery Institute
Discovery and Characterization of Novel ULK1/2 Inhibitors and Their Ability to Degrade ATG13, Inhibit Autophagy, and Treat KRAS Mutant Cancer

Sanford Burnham Prebys Medical Discovery Institute
Discovery and Characterization of PROTACs of Striatal-Enriched Protein Tyrosine Phosphatase (STEP) for Alzheimer’s Disease Therapeutics

Sanofi
Automation of Multiplex Biochemical Assays to Enhance Productivity and Reduce Cycle Time Using a Modular Robotic Platform

Scripps Research Institute
AlphaFold-RandomWalk: A Computational Pipeline to Sample Alternative Protein Conformations

Scripps Research Institute
Computational Modeling-Enabled Ligand Design for Asymmetric C(sp3)-H Diversification of Thioethers

Septerna
Unlocking the Power of Open DEL Libraries: A Scalable Data Analysis Platform

Sygnature Discovery Ltd.
Charmed in Action: Combinatorial High-Throughput Assembly and Review of Molecular Degraders

Sygnature Discovery Ltd.
FBDD Approaches to Tackle Emerging Multi-Component Therapeutic Targets

University Health Network
Total Synthesis of LXB4 and Related Chemical Probe Analogs for Target Deconvolution

University of California, Irvine
DEL in a Gel: Activity-Based DNA-Encoded Library Screening at the Attomole Scale with Magnetic Hydrogel Particles

University of California, Irvine
Developing a Phenotypic Screening Platform for DNA-Encoded Libraries in 2D Tissue Culture

University of California, San Francisco
Lysine Reactive Probes for the PHD3 Domain of KDM5A

University of Florida, Gainesville
Disulfide-Bond Disrupting Agents: Structure-Activity Relationships of Fluorinated Bioisosteres and Fluorescent Probe Design for Bioimaging

University of Iowa
Structure-Based Discovery of a Novel and Selective H. Pylori Antibacterial Class

University of Miami
Kinome-Wide Virtual Screening via Multi-Task Deep Learning for Small Molecular Drug Discovery in Cancer

University of Michigan
Development of PRC1 Inhibitors Employing Fragment-Based Approach and NMR-Guided Optimization

University of Michigan
Structure-Based Development of ASH1L Inhibitors as Potent Anti-Leukemic Agents

Velocity Bio, Inc.
Allosteric Discovery by Design: Accelerated Small Molecule Discovery with High-Throughput Microfluidics for Parallelized Enzyme Assays and Affinity Selections

Vipergen Aps
DELs in Cells – Direct Screening for Molecular Glue

Virginia Commonwealth University
Development of Next Generation Inhibitors to Disrupt C-Terminal Binding Protein's Oncogenic Effects

Viva Biotech Ltd.
One Stop DEL Solution: Viva‘s High-Value, High-Capability DNA-Encoded Library Platform

X-Chem, Inc.
Discovery of Pks13 Inhibitors for the Treatment of Tuberculosis (TB) Through DNA-Encoded Chemical Library (DEL) Screening

X-Chem, Inc.
Mirror-Image RNA-Targeted DEL Screens

X-Chem, Inc.
Recent Trends, Limitations, and New Opportunities in Covalent Drug Discovery